Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1668c ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Rhinitis, Allergic, Anti-Allergic Agents.
Abstract (Originalsprache)
The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H1-antihistamine olopatadine hydrochloride (Patanase, and generics) and the corticosteroid mometasone furoate (Nasonex 24 HR Allergy, and generics), for treatment of seasonal allergic rhinitis symptoms in persons ≥12 years old.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1668c
Vancouver
Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1668c
BibTeX
@article{euvimed2023,
title = {Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1668c}
}
EUVIMED